Cardinal Health Inc. (CAH)
Cardinal Health, Inc. (CAH) Leerink's 2025 Global Healthcare Conference (Transcript)
Cardinal Health, Inc. (NYSE:CAH ) Leerink's 2025 Global Healthcare Conference Call March 12, 2025 8:40 AM ET Company Participants Aaron Alt - Chief Financial Officer Matt Sims - Investor Relations Conference Call Participants Mike Cherny - Leerink Mike Cherny Perfect. We'll get started here.
Watch These 3 Stocks for Solid Earnings Acceleration
Prairie Operating, Intuit and Cardinal Health are exhibiting strong earnings acceleration.
Are Investors Undervaluing Cardinal Health (CAH) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Should Value Investors Buy Cardinal Health (CAH) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Cardinal Health Analysts Raise Their Forecasts Following Upbeat Earnings
Cardinal Health CAH reported better-than-expected second-quarter financial results on Thursday.
Cardinal Health, Inc. (CAH) Q2 2025 Earnings Call Transcript
Cardinal Health, Inc. (NYSE:CAH ) Q2 2025 Earnings Conference Call January 30, 2025 8:30 AM ET Company Participants Matt Sims - Vice President, Investor Relations Jason Hollar - Chief Executive Officer Aaron Alt - Chief Financial Officer Conference Call Participants John Stansel - JPMorgan Erin Wright - Morgan Stanley Allen Lutz - Bank of America Elizabeth Anderson - Evercore Michael Cherny - Leerink Partners Eric Percher - Nephron Kevin Caliendo - UBS Eric Coldwell - Baird Daniel Grosslight - Citi Steven Valiquette - Mizuho Charles Rhyee - TD Cowen Brian Tanquilut - Jefferies Operator Hello, and welcome to the Second Quarter Fiscal Year 2025 Cardinal Health Inc. Earnings Conference Call. My name is George, and I'll be coordinator for today's event.
CAH Q2 Earnings and Sales Beat Estimates, 2025 EPS View Raised
Cardinal Health's second-quarter fiscal 2025 results benefit from solid Other segment revenue growth. However, OptumRx contract expiry hurts Pharmaceutical segment sales.
Here's Why Cardinal Health (CAH) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Cardinal (CAH) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Cardinal (CAH) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Wall Street Analysts Think Cardinal (CAH) Is a Good Investment: Is It?
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Cardinal Health (CAH) Surpasses Q2 Earnings and Revenue Estimates
Cardinal Health (CAH) came out with quarterly earnings of $1.93 per share, beating the Zacks Consensus Estimate of $1.75 per share. This compares to earnings of $1.82 per share a year ago.
Cardinal Health lifts 2025 profit forecast on specialty drugs demand
Drug distributor Cardinal Health on Thursday raised its fiscal 2025 adjusted profit forecast as strong demand for costly specialty medicines and branded drugs drove sales at its pharmaceuticals unit.
